Legal & General Group Plc trimmed its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 12.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 51,352 shares of the company's stock after selling 7,103 shares during the quarter. Legal & General Group Plc owned 0.17% of Medpace worth $17,061,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in MEDP. R Squared Ltd purchased a new stake in Medpace during the fourth quarter valued at approximately $30,000. SBI Securities Co. Ltd. bought a new position in shares of Medpace during the 4th quarter valued at approximately $31,000. Jones Financial Companies Lllp lifted its position in Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after buying an additional 110 shares during the last quarter. Lindbrook Capital LLC boosted its stake in Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after buying an additional 29 shares during the period. Finally, Assetmark Inc. increased its position in Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after acquiring an additional 29 shares during the last quarter. Institutional investors own 77.98% of the company's stock.
Analyst Ratings Changes
A number of brokerages recently issued reports on MEDP. Leerink Partnrs raised Medpace to a "hold" rating in a research note on Monday, March 24th. Robert W. Baird upped their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. Truist Financial decreased their price objective on shares of Medpace from $347.00 to $333.00 and set a "hold" rating for the company in a report on Thursday, April 10th. TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and reduced their target price for the stock from $370.00 to $328.00 in a research report on Monday, April 14th. Finally, Mizuho lowered their price target on Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a report on Wednesday, April 9th. Ten investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $357.50.
View Our Latest Stock Report on MEDP
Medpace Stock Down 0.1 %
Shares of MEDP traded down $0.22 during trading on Friday, reaching $296.28. 698,291 shares of the company traded hands, compared to its average volume of 325,831. The stock has a 50-day simple moving average of $318.52 and a 200-day simple moving average of $333.31. The stock has a market cap of $8.96 billion, a PE ratio of 23.46, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a twelve month low of $272.00 and a twelve month high of $459.77.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.
Medpace Company Profile
(
Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
See Also
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
